Progressive cavitating leukoencephalopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:139447E75.2
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Progressive cavitating leukoencephalopathy (PCL) is an extremely rare inherited neurological disorder characterized by progressive white matter deterioration (leukoencephalopathy) with the formation of cystic cavities (cavitations) in the brain. The disease primarily affects the central nervous system, with MRI findings showing diffuse white matter abnormalities and progressive cystic degeneration predominantly in the cerebral and cerebellar white matter. PCL has been associated with mutations in genes involved in mitochondrial function, including APOPT1 (also known as C14orf153) and genes encoding mitochondrial respiratory chain complex components such as NDUFS1 and other mitochondrial-related genes. The ICD-10 classification under E75.2 reflects its categorization among sphingolipidoses and other lipid storage disorders, though the primary pathology relates to mitochondrial dysfunction affecting white matter integrity. Clinical features typically include progressive motor deterioration, spasticity, ataxia, cognitive decline, and in some cases seizures. Affected individuals may initially develop normally before experiencing neurological regression. The severity and rate of progression can vary, with some patients presenting in infancy or early childhood with rapid decline, while others may have a more protracted course. Additional features may include dystonia, visual impairment, and difficulty with speech and swallowing as the disease advances. There is currently no cure or disease-specific treatment for progressive cavitating leukoencephalopathy. Management is supportive and symptomatic, focusing on physical therapy, management of spasticity, seizure control with antiepileptic medications, nutritional support, and multidisciplinary rehabilitation. Genetic counseling is recommended for affected families. Research into mitochondrial therapies and potential targeted treatments is ongoing but remains in early stages.

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Progressive cavitating leukoencephalopathy.

View clinical trials →

No actively recruiting trials found for Progressive cavitating leukoencephalopathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Progressive cavitating leukoencephalopathy community →

No specialists are currently listed for Progressive cavitating leukoencephalopathy.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Progressive cavitating leukoencephalopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Progressive cavitating leukoencephalopathyForum →

No community posts yet. Be the first to share your experience with Progressive cavitating leukoencephalopathy.

Start the conversation →

Latest news about Progressive cavitating leukoencephalopathy

No recent news articles for Progressive cavitating leukoencephalopathy.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Progressive cavitating leukoencephalopathy

What is Progressive cavitating leukoencephalopathy?

Progressive cavitating leukoencephalopathy (PCL) is an extremely rare inherited neurological disorder characterized by progressive white matter deterioration (leukoencephalopathy) with the formation of cystic cavities (cavitations) in the brain. The disease primarily affects the central nervous system, with MRI findings showing diffuse white matter abnormalities and progressive cystic degeneration predominantly in the cerebral and cerebellar white matter. PCL has been associated with mutations in genes involved in mitochondrial function, including APOPT1 (also known as C14orf153) and genes enc

How is Progressive cavitating leukoencephalopathy inherited?

Progressive cavitating leukoencephalopathy follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.